Pfizer Aktie 962004 / US7170811035
37.65
USD
0.05
USD
0.13%
01:59:39
NDN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.95 |
| Vanguard Group, Inc. (Subfiler) | 8.61 |
| State Street Corp. | 5.02 |
| Capital Research & Management Co. (World Investors) | 4.12 |
| Wellington Management Co. LLP | 3.90 |
| Vanguard Total Stock Market ETF | 3.11 |
| BlackRock Fund Advisors | 3.06 |
| Vanguard 500 Index Fund | 2.34 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Geode Capital Management LLC | 1.95 |
| Charles Schwab Investment Management, Inc. | 1.49 |
| Washington Mutual Investors Fund | 1.43 |
| Fidelity 500 Index Fund | 1.11 |
| SPDR S&P 500 ETF Trust | 1.09 |
| Norges Bank (13F) | 1.09 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 92'400 | 88'300 | 78'500 | 79'000 | 83'000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.58 | 0.59 | 0.53 | 1.03 | 1.21 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 49'926 | 32'803 | 35'067 | 59'693 | 51'259 |
| Summe Anlagevermögen | 105'147 | 116'616 | 104'509 | 118'596 | 134'707 |
| Summe Aktiva | 159'422 | 167'489 | 154'229 | 181'476 | 197'205 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 41'740 | 53'474 | 41'271 | 41'395 | 39'046 |
| Summe Fremdkapital | 95'664 | 104'044 | 90'756 | 104'013 | 101'288 |
| Summe Eigenkapital | 63'758 | 63'445 | 63'473 | 77'463 | 95'917 |
| Summe Passiva | 159'422 | 167'489 | 154'229 | 181'476 | 197'205 |
Adresse
| 66 Hudson Boulevard East, 10001-2192 New York | |
| Telefon | +1 (212) 733-2323 |
| URL | http://www.pfizer.com |
Management
|
Aamir Malik
Chief Business Innovation Officer & Executive VP |
|
Aida Habtezion
Chief Medical Officer |
|
Albert Bourla
Chairman & Chief Executive Officer |
|
Andy Schmeltz
Senior VP-Commercial Strategy & Innovation |
|
Angela Hwang
Chief Commercial Officer |
|
Annaliesa Anderson
SVP, Head-Vaccine Research & Development |
|
Barbara J. Dalton
Vice President-Worldwide Business Development |
|
Bryan Supran
Senior Vice President & Deputy General Counsel |
|
Christopher J. Stevo
Chief Investor Relations Officer & Senior VP |
|
Dan R. Littman
Independent Director |
|
Daniella Gigante
Executive Director-Talent Acquisition |
|
David DeMicco
Head-Medical Affairs & Global Innovative Products |
|
David M. Denton
Chief Financial Officer & Executive Vice President |
|
Deborah Baron
Senior VP-Worldwide Business Development |
|
Denis Patrick
Executive Director & Vice President-WRDM |
|
Donna Wartski
Dir-Med Outcomes Specialist, US Medical Affairs |
|
Douglas M. Lankler
Executive Vice President & General Counsel |
|
Eva Grut-Aandahl
Vice President & Head-EU Government Affairs |
|
Gordon Loh
Senior Vice President-Corporate Audit |
|
Hakan Sakul
Vice President & Head-Diagnostics |
|
Helen H. Hobbs
Independent Director |
|
James C. Smith
Independent Director |
|
James Quincey
Independent Director |
|
Jeff Settleman
Co-Chief Scientific Officer |
|
Jennifer B. Damico
Chief Accounting Officer, EVP & Controller |
|
John DeYoung
Vice President-Worldwide Business Development |
|
Joseph J. Echevarria
Independent Director |
|
Lidia L. Fonseca
Executive VP, Chief Technology & Digital Officer |
|
Margaret M. Madden
Secretary, Chief Governance Counsel & Senior VP |
|
Maria Rivas
Chief Medical Affairs Officer |
|
Markus Green
Vice President & Assistant General Counsel |
|
Michael McDermott
Chief Global Supply Officer & Executive VP |
|
Mikael Dolsten
Co-Chief Scientific Officer & President-Research |
|
Patrice Ettinger
Chief Privacy Offucer |
|
Payal Sahni Becher
Chief People Officer & Executive Vice President |
|
Rady A. Johnson
EVP, Chief Compliance, Quality & Risk Officer |
|
Ronald E. Blaylock
Independent Director |
|
Sally Susman
Chief Corporate Affairs Officer & Executive VP |
|
Scott Gottlieb
Independent Director |
|
Shantanu Narayen
Lead Independent Director |
|
Suneet Varma
President-US Oncology Business Unit |
|
Susan D. Desmond-Hellmann
Independent Director |
|
Susan J. Hockfield
Independent Director |
|
Suzanne Nora Johnson
Independent Director |
|
William Pao
Chief Development Officer & Executive VP |